Position in TMO
as of Jun 30, 2026
· filed Aug 18, 2026
Position Value
$934,535
-$2,951,992 QoQ
Shares Held
1,864
-76.4% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.09%
of 13F equity value
Holder Rank
#1,477
of 2,606 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TMO Over Time
Shares Held
Position Value (USD)
Derivatives in TMO
reported options exposure · as of Mar 31, 2025CallValue
$0
CallShares
0
PutValue
$3,854,907
PutShares
7,747
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Diagnostics & Research
Healthcare · as of Jun 30, 2026Fulcrum Asset Management LLP holds $8,929,864 across 7 Diagnostics & Research names. TMO ranks #3 (10.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MTD |
Mettler Toledo International Inc/
|
3,240 | $4,139,132 | |
| 2 | DHR |
Danaher Corp /De/
|
16,459 | $3,135,110 | |
| 3 | TMO |
Thermo Fisher Scientific Inc.
This page
|
1,864 | $934,535 | |
| 4 | IDXX |
Idexx Laboratories Inc /De
|
1,055 | $555,394 | |
| 5 | ILMN |
Illumina, Inc.
|
897 | $157,719 | |
| 6 | VCYT |
Veracyte, Inc.
|
104 | $6,107 | |
| 7 | NEO |
Neogenomics Inc
|
128 | $1,867 |
All Filings in TMO
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $934,535 | 1,864 | Shares | Sole | 2026-08-18 | |
| 2026-03-31 | $3,886,527 | 7,907 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $4,524,345 | 7,808 | Shares | Sole | 2026-02-05 | |
| 2025-09-30 | $3,899,075 | 8,039 | Shares | Sole | 2025-11-24 | |
| 2025-06-30 | $3,349,505 | 8,261 | Shares | Sole | 2025-11-24 | |
| 2025-03-31 | $3,854,907 | 7,747 | Put | Sole | 2025-04-24 | |
| No filing history on record for this holder in this stock. | ||||||